Relevance of the novel IASLC/ATS/ERS classification of lung adenocarcinoma in advanced disease

European Respiratory Journal

Volumn 43, Issue 5, 2014, Pages 1439-1447

  Campos Parra, Alma D ^a   Avilés, Alejandro ^a   Contreras Reyes, Susana ^a   Rojas Marín, Carlos E ^a   Sánchez Reyes, Roberto ^a   Borbolla Escoboza, Rafael J ^b   Arrieta, Oscar ^a  

^a INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^b Oncology Center   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; NAVELBINE; PACLITAXEL; ANTINEOPLASTIC AGENT;

ACINAR PREDOMINANT LUNG ADENOCARCINOMA; ADULT; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; EARLY CANCER; EGFR GENE; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEPIDIC PREDOMINANT LUNG ADENOCARCINOMA; LUNG ADENOCARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MICROPAPILLARY PREDOMINANT LUNG ADENOCARCINOMA; OVERALL SURVIVAL; PAPILLARY PREDOMINANT LUNG ADENOCARCINOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SEX DIFFERENCE; SOLID PREDOMINANT LUNG ADENOCARCINOMA; THORAX PAIN; TREATMENT RESPONSE; TUMOR BIOPSY; ADENOCARCINOMA; AGED; CLASSIFICATION; DISEASE FREE SURVIVAL; GENETICS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; ORGANIZATION AND MANAGEMENT; PROGNOSIS; PULMONOLOGY; SEVERITY OF ILLNESS INDEX; STANDARDS; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; PULMONARY MEDICINE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84899850134     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00138813     Document Type: Article

References (20)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Arrieta O, Guzmán-de Alba E, Alba-López LF, et al. Consenso nacional de diagnóstico y tratamiento del cáncer de pulmón de células no pequeñas [National Consensus on the diagnosis and treatment of non-small cell lung cancer]. Rev Inv Clin 2013; 65: supl., 1: S5-S64.
3. Ruíz-Godoy L, Rizo Rios P, Sánchez Cervantes F, et al. Mortality due to lung cancer in Mexico. Lung Cancer 2007; 58: 184-190.
4. Devesa SS, Bray F, Vizcaino AP, et al. International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer 2005; 117: 294-299.
5. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/EuropeanRespiratory Society: international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011; 6: 244-285.
6. Yoshizawa A, Motoi N, Riely GJ, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: Prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol 2011; 24: 653-664.
7. Russell PA, Wainer Z, Wright GM, et al. Does lung adenocarcinoma subtype predict patient survival? A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification. J Thorac Oncol 2011; 6: 1496-1504.
8. Warth A, Muley T, Meister M, et al. The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stageindependent predictor of survival. J Clin Oncol 2012; 30: 1438-1446.
9. Yoshizawa A, Sumiyoshi S, Sonobe M, et al. Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRASgene mutations: analysis of 440 Japanese patients. J Thorac Oncol 2013; 8: 52-61.
10. Travis WD, Brambilla E, Muller-Hermelink HK, et al. Eds. Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart. World Health Organization Classification of Tumors. Lyon, IARC Press, 2004.
11. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011; 6: 244-285.
12. Azzoli CG, Temin S, Aliff T, et al. 2011 focused update of 2009 American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage iv non-small-cell lung cancer. J Clin Oncol 2011; 29: 3825-3831.
13. Miller VA, Hirsch FR, Johnson DH. Systemic therapy of advanced bronchioloalveolar cell carcinoma: challenges and opportunities. J Clin Oncol 2005; 23: 3288-3293.
14. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-smallcell lung cancer. N Engl J Med 2002; 346: 92-98.
15. Miller VA, Hirsch FR, Johnson DH. Systemic therapy of advanced bronchioloalveolar cell carcinoma: challenges and opportunities. J Clin Oncol 2005; 23: 3288-3293.
16. Sarantopoulos GP, Gui D, Shintaku P, et al. Immunohistochemical analysis of lung carcinomas with pure or partial bronchioloalveolar differentiation. Arch Pathol Lab Med 2004; 128: 406-414.
17. Aida S, Shimazaki H, Sato K, et al. Prognostic analysis of pulmonary adenocarcinoma subclassification with special consideration of papillary and bronchioloalveolar types. Histopathol 2004; 45: 468-476.
18. Yokose T, Suzuki K, Nagai K, et al. Favorable and unfavorable morphological prognostic factors in peripheral adenocarcinoma of the lung 3 cm or less in diameter. Lung Can 2000; 29: 179-188.
19. Shim HS, Lee da H, Park EJ, et al. Histopathologic characteristics of lung adenocarcinomas with epidermal growth factor receptor mutations in the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification. Arch Pathol Lab Med 2011; 135: 1329-1334.
20. Yang JC, Shih JY, Su WC, et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol 2012; 13: 539-548.